EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Thu, 07.08.2025
Galenica Group sales grew by 5.0% to CHF 1,995.4 million in the first half of 2025.
Adjusted EBIT1 increased by 10.9% to CHF 109.9 million – supported by positive one-time effects of CHF 5.4 million.
Galenica is therefore raising its EBIT guidance and now expects growth between 7% and 9% (previously growth between 4% and 6%).
Guidance for 2025 ...
Press releaseAd hoc announcement pursuant to Art. 53 LR
By acquiring the Labor Team Group, Galenica is adding a leading Swiss diagnostic service provider to its healthcare network.
The strategic acquisition will enable Galenica to further expand its offerings in the physicians segment.
This opens up the possibility of offering selected additiona...
Press releaseAd hoc announcement pursuant to Art. 53 LR
Sales growth of 4.7% to CHF 1,314.2 million
Strong growth in all key business areas
Guidance for 2025 confirmed – sales growth of 3-5% and EBIT1 growth of 4-6% expected
With a sales growth of 4.7% to CHF 1,314.2 million in the first four months, the Galenica Group made an excellent start t...
Galenica AG
/ Key word(s): AGMEGM
Galenica Annual General Meeting approves all motions and elects new member of the Board of Directors 10.04.2025 / 18:12 CET/CEST
Press release
All motions of the Board of Directors approved with broad consensus
Nadine Balkanyi-Nordmann elected as a new member of the Board of Directors
Divide...
Press releaseAd hoc announcement pursuant to Art. 53 LR
With sales up 4.7% in the 2024 financial year, the Galenica Group grew strongly and generated consolidated net sales of CHF 3,921.1 million. As a result, Galenica outperformed market growth and gained market share in all its main business areas.
Adjusted1 EBIT increased by 10.3% to CHF 211.0 ...
Galenica AG
/ Key word(s): Personnel
Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors 23.01.2025 / 07:00 CET/CEST
Press release
Nadine Balkanyi-Nordmann, an experienced legal, compliance and governance expert, will be recommended for election as a member of the Board of Directors at the next Annual Genera...
Press releaseAd hoc announcement pursuant to Art. 53 LR
Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
Following a solid increase ...
Press releaseAd hoc announcement pursuant to Art. 53 LR
Following solid sales growth of 2.6% in the first half of 2024, Galenica grew more strongly again in the third quarter and generated net sales of CHF 2,864.8 million to the end of September 2024. With growth of 4.1%, Galenica outperformed the growth of the overall pharmaceutical market (+2.9%,...
Galenica AG
/ Key word(s): Strategic Company Decision
Expansion of the Executive Committee and handover of the position of CFO 06.08.2024 / 07:00 CET/CEST
Press release
Galenica is aligning its pharmacy business to an even greater focus on customers. With Stephan Mignot, Marketing for the pharmacies will have a direct seat on ...
Press releaseAd hoc announcement pursuant to Art. 53 LR
Galenica Group sales grew by 2.6% to CHF 1,900.0 million in the first half of 2024. Both the “Products & Care” segment and the “Logistics & IT” segment contributed to the sales growth, with growth of 3.1% and 3.0% respectively. As a result, Galenica Group sales developed more dynamical...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .